Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16140868 | 0.87 | L3MBTL1 (0.48) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL16115868 | 0.85 | L3MBTL1 (0.53) | MAPTL3MBTL1TDP1KMT2AMPO | |
| SCHEMBL19902885 | 0.82 | KMT2A (0.54) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL28709251 | 0.81 | KAT6A (0.49) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL28709234 | 0.80 | MAPT (0.47) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL30474518 | 0.79 | KMT2A (0.55) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL28699689 | 0.79 | KMT2A (0.55) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL28709403 | 0.78 | SMN1; SMN2 (0.43) | MAPTL3MBTL1TDP1HPGDKMT2A | |
| SCHEMBL17518823 | 0.77 | MPO (0.51) | MAPTL3MBTL1TDP1KMT2AMPO | |
| SCHEMBL25624042 | 0.77 | MAPT (0.44) | MAPTL3MBTL1TDP1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450312-B2 | Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10450312-B2 | Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180291022-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-11 | — | — | US | disclosed |
| US-10023568-B2 | Naphthyridine derivatives useful as αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-17 | — | — | US | disclosed |
| US-10023568-B2 | Naphthyridine derivatives useful as αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-17 | — | — | US | disclosed |
| US-10023568-B2 | Naphthyridine derivatives useful as αvβ6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-17 | — | — | US | disclosed |
| EP-2989100-B1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-02-28 | — | — | EP | disclosed |
| EP-2989100-B1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-02-28 | — | — | EP | disclosed |
| US-20160280705-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-29 | — | — | US | disclosed |
| US-20160280705-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-29 | — | — | US | disclosed |
| US-20160280705-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-29 | — | — | US | disclosed |
| CN-105189499-B | naphthyridine derivatives useful as avbeta6 integrin antagonists | 葛兰素史克知识产权开发有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105189499-A | Can be used as alphavβ6Naphthyridine derivatives of integrin antagonists | GLAXOSMITHKLINE IP DEV CO LTD | 2015-12-23 | — | — | CN | disclosed |
| WO-2014154725-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280705-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB1 | MAPT 4413/4885L3MBTL1 1856/4885TDP1 3903/4885 |
| US-10450312-B2 | Naphthyridine derivatives useful as alpha-V-beta-6 integrin antagonists | ITGB6, ITGA6, ITGB1 | MAPT 4413/4885L3MBTL1 1856/4885TDP1 3903/4885 |
| US-20180291022-A1 | NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB1 | MAPT 4413/4885L3MBTL1 1856/4885TDP1 3903/4885 |
| US-10023568-B2 | Naphthyridine derivatives useful as αvβ6 integrin antagonists | ITGB6, ITGA6, ITGB3 | MAPT 4049/4885L3MBTL1 2812/4885TDP1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.